Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
- Conditions
- LymphomaMultiple Myeloma
- Interventions
- Drug: LenalidomideDrug: DexamethasoneDrug: Dexamethasone (Oral)Drug: Dexamethasone (IV)Biological: Elotuzumab (BMS-901608; HuLuc63)
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 646
- Registration Number
- NCT01239797
- Locations
- 🇺🇸
Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States
🇺🇸Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Ut Southwestern Medical Center, Dallas, Texas, United States
Randomized Study for Effectiveness and Safety Evaluation of Dexamethasone 0.5 mg + Fumarate Clemastine 1 mg Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 96
- Registration Number
- NCT01239719
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
- Conditions
- Myeloma
- Interventions
- Drug: PaliferminDrug: DexamethasoneDrug: GemcitabineDrug: BusulfanDrug: MelphalanProcedure: Stem Cell TransplantDrug: G-CSF
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT01237951
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 250
- Registration Number
- NCT01237249
- Locations
- 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸Hospital Ramón y Cajal, Madrid, Spain
🇪🇸Hospital Clínico de Valencia., Valencia, Spain
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
- Conditions
- SarcomaOsteosarcomaWilm's TumorLymphomaBrain Neoplasms
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT01236586
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸St. Jude Childrens Research Hospital, Memphis, Tennessee, United States
Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL
- Conditions
- Leukemia
- Interventions
- Drug: AmsacrineDrug: CyclophosphamideDrug: ClofarabineDrug: CytarabineDrug: DexamethasoneDrug: Daunorubicin hydrochlorideDrug: Doxorubicin hydrochlorideDrug: Etoposide phosphateDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseDrug: MethylprednisoloneDrug: ThioguanineDrug: Vincristine sulfateRadiation: Whole-brain radiation therapy
- First Posted Date
- 2010-10-26
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 745
- Registration Number
- NCT01228331
- Locations
- 🇩🇪
Universitaetsklinikum Duesseldorf, Duesseldorf, Germany
🇩🇪University Medical Center Hamburg - Eppendorf, Hamburg, Germany
🇩🇪Johannes Gutenberg University, Mainz, Germany
Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 3762
- Registration Number
- NCT01225874
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 40
- Registration Number
- NCT01222260
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Columbia University, New York, New York, United States
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01217957
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Mt Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
Trimodality Management of T1b Esophageal Cancers
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT01217060
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.